Cellular Sciences, Inc.
Flemington, NJ, US· latest recorded location
Cellular Sciences, Inc. is named on 11 US grants and 3 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 11
- Published applications
- 3
- Inventors
- 2
- Granted in 2026 so far
- 1
- Most recent grant
- 28 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 1 | 0 |
| 2004 | 1 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 1 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 0 | 0 |
| 2020 | 1 | 1 |
| 2021 | 0 | 0 |
| 2022 | 1 | 0 |
| 2023 | 1 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 14 documents
Recent patents
- Compositions and methods to reduce or eliminate nasal biofilms and mucus barriers allowing sodium pyruvate to increase the synthesis of nitric oxide and eliminate nasal infections and their toxins that cause lung, nerve and brain damage28 Apr 2026US 12,611,389 B1
- Method and composition for the reduction of viral replication, duration and spread of the COVID-19 and the flu18 Apr 2023US 11,628,186 B2
- Synergistic compositions to stimulate the synthesis of human lung and sinus surfactants to decrease coughing, increase FEV-1/FVC ratios, decrease lung fibrosis, by increasing apoptosis of myofibroblasts26 Apr 2022US 11,311,505 B2
- Compositions and methods for the treatment and prevention of chronic hypoxemia and dyspnea27 Oct 2020US 10,813,893 B2
- Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells14 Feb 2012US 8,114,907 B2
- Methods for the treatment of chronic hypoxemia and inhibiting lung fibrosis in patients with pulmonary fibrosis with and without COPD16 Jan 2020US 2020/0016102 A1
- Compositions and Methods for the Treatment and Prevention of Chronic Hypoxemia and Dyspnea.30 Aug 2018US 2018/0243246 A1
- Method for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of inflammatory agents in mammalian cells12 Feb 2009US 2009/0041738 A1
Most cited
By later US patents
- Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide25US 6,689,810 B22004
- Method and composition for treating mammalian diseases caused by inflammatory response9US 5,952,384 A1999
- Method and composition for treating mammalian diseases caused by inflammatory response7US 5,798,388 A1998
- Method and composition for treating mammalian disease caused by inflammatory response7US 5,939,459 A1999
- Method for treating bronchial constriction and bronchospasm5US 6,623,723 B22003